GOT1 and metabolic dysfunction-associated steatotic liver disease: This score combines the results of liver stiffness measurement (LSM), steatosis assessment by controlled attenuation parameter (CAP) and aspartate aminotransferase (AST) and has been developed to identify patients with NASH, elevated NAFLD activity score (NAS ≥ 4) and significant fibrosis (fibrosis stage F ≥ 2) amongst those with NAFLD [19].